# Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML

> **NCT04402723** · PHASE1 · TERMINATED · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 8 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** Donafenib

## Key facts

- **NCT ID:** NCT04402723
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-06
- **Primary completion:** 2022-02-09
- **Final completion:** 2022-02-09
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Corporate policy adjustments
- **Last updated:** 2022-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04402723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04402723, "Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04402723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*